These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 19696701

  • 1. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
    Stepien KE, Rosenfeld PJ, Puliafito CA, Feuer W, Shi W, Al-Attar L, Dubovy SR, Murray TG, Davis JL, Lee WH, Schwartz SG, Smiddy WE, Berrocal AM, Flynn HW.
    Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
    Chang TS, Kokame G, Casey R, Prenner J, Feiner L, Anderson N.
    Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
    [Abstract] [Full Text] [Related]

  • 8. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.
    Fong DS, Custis P, Howes J, Hsu JW.
    Ophthalmology; 2010 Feb; 117(2):298-302. PubMed ID: 19969368
    [Abstract] [Full Text] [Related]

  • 9. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G.
    Retina; 2006 Feb; 26(5):495-511. PubMed ID: 16770255
    [Abstract] [Full Text] [Related]

  • 10. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
    Tao Y, Jonas JB.
    Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
    [Abstract] [Full Text] [Related]

  • 11. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C, Michels S, Prager F, Garhoefer G, Georgopoulos M, Polak K, Schmidt-Erfurth U.
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [Abstract] [Full Text] [Related]

  • 12. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
    Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML.
    Retina; 2007 Aug; 27(4):439-44. PubMed ID: 17420695
    [Abstract] [Full Text] [Related]

  • 13. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ.
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [Abstract] [Full Text] [Related]

  • 14. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.
    Garg S, Brod R, Kim D, Lane RG, Maguire J, Fischer D.
    Clin Exp Ophthalmol; 2008 Apr; 36(3):252-6. PubMed ID: 18412594
    [Abstract] [Full Text] [Related]

  • 15. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS.
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [Abstract] [Full Text] [Related]

  • 16. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [Abstract] [Full Text] [Related]

  • 17. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 Jul; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 18. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration.
    Kent JS, Iordanous Y, Mao A, Powell AM, Kent SS, Sheidow TG.
    Can J Ophthalmol; 2012 Apr; 47(2):159-64. PubMed ID: 22560422
    [Abstract] [Full Text] [Related]

  • 19. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial.
    Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, Houranieh A, Feinberg EB.
    Eye (Lond); 2010 Nov; 24(11):1708-15. PubMed ID: 20885427
    [Abstract] [Full Text] [Related]

  • 20. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.